CN109069607A - 用于疟疾疫苗中的新型抗原 - Google Patents

用于疟疾疫苗中的新型抗原 Download PDF

Info

Publication number
CN109069607A
CN109069607A CN201780012190.0A CN201780012190A CN109069607A CN 109069607 A CN109069607 A CN 109069607A CN 201780012190 A CN201780012190 A CN 201780012190A CN 109069607 A CN109069607 A CN 109069607A
Authority
CN
China
Prior art keywords
asn
seq
ile
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780012190.0A
Other languages
English (en)
Chinese (zh)
Inventor
若昂·卡洛斯·阿吉亚尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Camrius International
Original Assignee
Camrius International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camrius International filed Critical Camrius International
Publication of CN109069607A publication Critical patent/CN109069607A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780012190.0A 2016-02-17 2017-02-13 用于疟疾疫苗中的新型抗原 Pending CN109069607A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296464P 2016-02-17 2016-02-17
US62/296,464 2016-02-17
PCT/US2017/017722 WO2017142843A1 (en) 2016-02-17 2017-02-13 Novel antigen for use in malaria vaccine

Publications (1)

Publication Number Publication Date
CN109069607A true CN109069607A (zh) 2018-12-21

Family

ID=59559460

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780012190.0A Pending CN109069607A (zh) 2016-02-17 2017-02-13 用于疟疾疫苗中的新型抗原

Country Status (10)

Country Link
US (2) US10195260B2 (https=)
EP (1) EP3416681B1 (https=)
JP (2) JP7261013B2 (https=)
KR (1) KR20180108754A (https=)
CN (1) CN109069607A (https=)
AU (1) AU2017219613B2 (https=)
BR (1) BR112018016912A2 (https=)
CA (1) CA3014196A1 (https=)
WO (1) WO2017142843A1 (https=)
ZA (1) ZA201805547B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116457012A (zh) * 2020-06-29 2023-07-18 帕斯公司 红细胞前期疟疾疫苗

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7261013B2 (ja) 2016-02-17 2023-04-19 カムリス インターナショナル インコーポレイテッド マラリアワクチンにおいて使用するための新規抗原
CN110703326B (zh) * 2019-10-11 2021-07-16 中国石油化工股份有限公司 一种基于中小偏移距道集的fvo反演方法
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
IE20210235A1 (en) * 2020-10-20 2023-08-16 Longhorn Vaccines & Diagnostics Llc Immunogenic antigens
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
JP2025533527A (ja) 2022-09-23 2025-10-07 ビオンテック・ソシエタス・エウロパエア Ｐｌａｓｍｏｄｉｕｍ ＣＳＰ抗原の送達のための組成物及び関連方法
WO2024064931A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
EP4669348A1 (en) 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
IL325865A (en) 2023-07-21 2026-03-01 BioNTech SE Compositions for administering Plasmodium antigens and related methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863970A (zh) * 2010-05-18 2010-10-20 吉林大学 一种可抑制恶性疟原虫侵入的抗Pf332-DBL区单克隆抗体
US20150366958A1 (en) * 2010-11-09 2015-12-24 Lin Chen Treatment and prevention of malaria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108272A2 (en) * 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
GB201318084D0 (en) * 2013-10-11 2013-11-27 Isis Innovation Malaria vaccination
JP7261013B2 (ja) 2016-02-17 2023-04-19 カムリス インターナショナル インコーポレイテッド マラリアワクチンにおいて使用するための新規抗原

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863970A (zh) * 2010-05-18 2010-10-20 吉林大学 一种可抑制恶性疟原虫侵入的抗Pf332-DBL区单克隆抗体
US20150366958A1 (en) * 2010-11-09 2015-12-24 Lin Chen Treatment and prevention of malaria

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HALL N.等: "XP_001350937.3", 《GENBANK》 *
朱垚吉等: "疟疾疫苗候选蛋白及其抗原性研究概况", 《中国病原生物学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116457012A (zh) * 2020-06-29 2023-07-18 帕斯公司 红细胞前期疟疾疫苗

Also Published As

Publication number Publication date
JP2019505560A (ja) 2019-02-28
US10195260B2 (en) 2019-02-05
AU2017219613A1 (en) 2018-08-30
JP7261013B2 (ja) 2023-04-19
ZA201805547B (en) 2023-01-25
AU2017219613B2 (en) 2022-04-07
US20190117752A1 (en) 2019-04-25
WO2017142843A1 (en) 2017-08-24
BR112018016912A2 (pt) 2018-12-26
WO2017142843A8 (en) 2018-09-07
EP3416681B1 (en) 2026-01-21
US20170232091A1 (en) 2017-08-17
JP2022037078A (ja) 2022-03-08
EP3416681A1 (en) 2018-12-26
CA3014196A1 (en) 2017-08-24
KR20180108754A (ko) 2018-10-04
US11793868B2 (en) 2023-10-24
EP3416681A4 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
AU2017219613B2 (en) Novel antigen for use in malaria vaccine
JP5108521B2 (ja) マラリア初回免疫／追加免疫ワクチン
RU2356577C9 (ru) Способы вакцинации против малярии
Grifantini et al. Multi‐plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid
NO319844B1 (no) Vaksinesammensetning og anvendelse derav
US20120015000A1 (en) Malaria vaccine of self-assembling polypeptide nanoparticles
WO2005046621A2 (en) Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
Shital et al. An update on recombinant vaccines against leishmaniasis
Almeida et al. Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein
US10919946B2 (en) Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the PFR1 protein of leishmania infantum with specific immunodominant epitopes
Schneider et al. Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection
WO2011031317A2 (en) Vaccine for control of trypanosoma cruzi infection and chagas disease
BG65569B1 (bg) Химерен ген кодиращ антигенни детерминанти на четири протеина на l. infantum
EP2987502B1 (en) Peptide adjuvants
HK40001561B (en) Novel antigen for use in malaria vaccine
HK40001561A (en) Novel antigen for use in malaria vaccine
US20080213318A1 (en) Malaria MSP-1 C-terminal enhanced subunit vaccine
Seid Rational vaccine development for malaria from genomic sequence information
Dhanawat et al. Development in malarial vaccine: A review.
Ghosh 61st Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), Atlanta, Georgia, USA-November 12-15, 2012
Hill et al. The Requirement for Potent Adjuvants To
HK1153412A (en) Methods for vaccinating against malaria
HK1100121B (en) Malaria prime/boost vaccines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination